TIMI 37A

TIMI 37A evaluated the efficacy, safety, and pharmacokinetics of INO-1001, a poly(ADP-ribose) polymerase in patients with ST-segment elevation myocardial infarction.

MAIN RESULTS:
A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial
TIMI 37A
J Thromb Thrombolysis. 2009 May;27(4):359-64.

PRESENTATIONS

TIMI 37A Slides

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close